• Earlier this month, Spyre Therapeutics announced the launch of SPY772, a combination of its anti-TL1A and anti-IL-17A/F antibodies in preclinical development, alongside the initiation of SKYLIGHT, a randomized Phase 2 proof-of-concept trial in moderate-to-severe Hidradenitis Suppurativa using background bimekizumab and targeting HiSCR75 at Week 16.
• This dual-pathway approach in an area of high unmet medical need adds another layer to Spyre’s pipeline ambitions and could reshape how investors think about its immunology portfolio mix.
• With this new dual-inhibition Phase 2 trial in Hidradenitis Suppurativa underway, we’ll examine how it influences Spyre Therapeutics’ investment narrative.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 28 best rare earth metal stocks of the very few that mine this essential strategic resource.

What Is Spyre Therapeutics' Investment Narrative?

To own Spyre Therapeutics here, you have to believe its TL1A platform can translate early UC data into a coherent, durable immunology franchise, despite zero revenue and continuing losses. The launch of SPY772 and the SKYLIGHT Phase 2 trial in Hidradenitis Suppurativa deepen that story, but they do not really change the near term catalyst map, which is still dominated by multiple Phase 2 UC and rheumatology readouts through 2026. Where this new program matters is on risk: it adds another capital intensive trial to an already loss making model, soon after substantial equity raises and index removals, at a time when the share price has already delivered a very large one year return. That leaves less room for clinical missteps before valuation and dilution worries come back into focus.

However, one key financing risk could matter more than the new HS trial. In light of our recent valuation report, it seems possible that Spyre Therapeutics is trading beyond its estimated value.

Exploring Other Perspectives

Only one fair value estimate from the Simply Wall St Community pegs Spyre at US$122.14, showing little dispersion in expectations so far. Set against a rich price to book and a crowded 2026 Phase 2 calendar, this single anchor highlights how important it is to weigh other views on execution risk, funding needs and trial outcomes before deciding where you stand.

Explore another fair value estimate on Spyre Therapeutics - why the stock might be worth as much as 19% more than the current price!

Decide For Yourself

Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Spyre Therapeutics research is our analysis highlighting 4 important warning signs that could impact your investment decision.
• Our free Spyre Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Spyre Therapeutics' overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• AI is about to change healthcare. These 43 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Explore 25 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Uncover the next big thing with 19 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.